Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) EVP Michael Parini sold 10,829 shares of the company’s stock in a transaction on Wednesday, July 19th. The shares were sold at an average price of $161.00, for a total transaction of $1,743,469.00. Following the completion of the sale, the executive vice president now directly owns 37,309 shares in the company, valued at $6,006,749. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.
Michael Parini also recently made the following trade(s):
- On Thursday, August 3rd, Michael Parini sold 2,330 shares of Vertex Pharmaceuticals stock. The shares were sold at an average price of $155.72, for a total transaction of $362,827.60.
Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) traded down 0.28% during trading on Friday, reaching $148.13. 887,138 shares of the company’s stock were exchanged. The stock has a 50-day moving average price of $146.73 and a 200 day moving average price of $117.81. Vertex Pharmaceuticals Incorporated has a 12 month low of $71.46 and a 12 month high of $167.85. The firm has a market cap of $37.35 billion, a price-to-earnings ratio of 142.30 and a beta of 1.77.
Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Wednesday, July 26th. The pharmaceutical company reported $0.39 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.06 by $0.33. The firm had revenue of $544.10 million during the quarter, compared to analyst estimates of $489.95 million. Vertex Pharmaceuticals had a net margin of 12.05% and a return on equity of 4.64%. The business’s revenue for the quarter was up 26.1% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.24 EPS. On average, analysts forecast that Vertex Pharmaceuticals Incorporated will post $1.60 EPS for the current year.
TRADEMARK VIOLATION WARNING: “Insider Selling: Vertex Pharmaceuticals Incorporated (VRTX) EVP Sells 10,829 Shares of Stock” was reported by BNB Daily and is owned by of BNB Daily. If you are reading this article on another domain, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this article can be read at https://www.baseball-news-blog.com/2017/08/19/vertex-pharmaceuticals-incorporated-vrtx-evp-sells-1743469-00-in-stock-updated-updated-updated.html.
Several hedge funds and other institutional investors have recently made changes to their positions in VRTX. Parametrica Management Ltd bought a new position in shares of Vertex Pharmaceuticals during the first quarter worth about $943,000. Oakmont Partners LLC bought a new position in shares of Vertex Pharmaceuticals during the first quarter worth about $219,000. Capstone Asset Management Co. increased its position in shares of Vertex Pharmaceuticals by 0.9% in the first quarter. Capstone Asset Management Co. now owns 25,428 shares of the pharmaceutical company’s stock worth $2,781,000 after buying an additional 230 shares during the period. Bank of Montreal Can increased its position in shares of Vertex Pharmaceuticals by 6.8% in the first quarter. Bank of Montreal Can now owns 158,740 shares of the pharmaceutical company’s stock worth $17,360,000 after buying an additional 10,160 shares during the period. Finally, National Pension Service increased its position in shares of Vertex Pharmaceuticals by 4.0% in the first quarter. National Pension Service now owns 200,779 shares of the pharmaceutical company’s stock worth $21,542,000 after buying an additional 7,809 shares during the period. Institutional investors own 94.89% of the company’s stock.
A number of research analysts recently issued reports on the stock. UBS AG reiterated a “buy” rating and set a $135.00 target price (up previously from $132.00) on shares of Vertex Pharmaceuticals in a research report on Friday, May 19th. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Vertex Pharmaceuticals in a research report on Sunday, April 30th. Cowen and Company restated a “buy” rating on shares of Vertex Pharmaceuticals in a report on Tuesday, August 1st. Maxim Group set a $195.00 price objective on shares of Vertex Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, July 27th. Finally, BMO Capital Markets restated an “outperform” rating and set a $182.00 price objective (up previously from $180.00) on shares of Vertex Pharmaceuticals in a report on Thursday, July 27th. Five research analysts have rated the stock with a hold rating, twenty-two have issued a buy rating and one has assigned a strong buy rating to the company. Vertex Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $162.88.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases. The Company is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and advancing its research and development programs in other indications.
Receive News & Ratings for Vertex Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.